Monograph
J07BC02 - Hepatitis A, Inactivated, Whole Virus |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hepatitis A, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated hepatitis A virus.
Therapeutic characteristics
The vaccine is indicated for the active immunization of adults and children over the age of 1against hepatitis A. It is administered by a single intramuscular injection. A booster dose is recommended after 6-12 months in order to obtain more persistent immunity.
Metabolism and pharmacokinetics
The hepatitis vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Havrix.
|
|
Tradenames
Avaxim · Havrix · Vaqta 
Avaxim · Havrix · Vaqta 
Avaxim · Havrix · Vaqta 
Avaxim · Havrix · Vaqta 
Avaxim · Havrix 
Havrix 
Avaxim Junior vaccine · Avaxim vaccine · Epaxal Berna · Epaxal vaccine · Havrix Junior Monodose vaccine · Havrix Monodose vaccine · Vaqta 
Avaxim · Havrix · Vaqta 
Havrix 
Avaxim · Havrix · Vaqta 
Avaxim · Havrix · Vaqta 
Havrix 
Avaxim · Havrix · Vaqta 
Avaxim · Havrix 
Avaxim · Havrix 
Avaxim · Havrix 
Avaxim 
Avaxim · Havrix · Vaqta 
Vaccines